Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-survey-about-90-hepatitis-c-patients-unaware-of-infection-and-majority-refuses-treatment
https://www.med.cuhk.edu.hk/press-releases/cuhk-survey-about-90-hepatitis-c-patients-unaware-of-infection-and-majority-refuses-treatment

CUHK Survey: About 90% Hepatitis C Patients Unaware of Infection and Majority Refuses Treatment

The Center for Liver Health of The Chinese University of Hong Kong (CUHK) and the Caritas Lok Heep Club jointly launched a ‘New Life, New Liver’ programme in 2009 to provide Hepatitis C virus (HCV) screening services and education for high-risk individuals who might have contracted HCV through sharing syringes.  Findings of the programme indicated that 56% of this high-risk group were diagnosed with HCV and over 90% of them were unaware of infection.  Among the patients, only 20% were willing to receive medical treatment which is quite harsh.

 

HCV is mainly transmitted through blood or body fluid and is the main cause of liver cirrhosis and liver cancer, affecting approximately 150 million people worldwide.  Hepatitis C is difficult to be detected during its early stage when the symptoms are not obvious.  Usually it will have progressed to liver failure or liver cancer when evident symptoms arise such as jaundice, dark urine or abdominal pain.

 

The ‘New Life, New Liver’ programme conducted between 2009 and 2012 screened a total of 234 individuals who were at high risk of contracting HCV. 130 subjects (56%) were found to carry the virus and 15 subjects (6.4%) had already developed cirrhosis.  Regrettably, among the HCV-carriers, only 69 (53%) were willing to be regularly observed by health care professionals, and just 26 patients (20%) decided to receive medical treatment.

 

Conventional medical treatment for HCV requires weekly injection of peginterferon which may incur numerous side effects including fever and depression.  The process is arduous and the success rate of eradicating the virus is just about 50%.  A participant of the programme described the treatment as grueling and disappointing as it failed to clear the HCV in his body.  In recent years, there have been new breakthroughs in HCV treatment using direct-acting antivirals (DAAs).  The latest antiviral drug can be administered alone and the success rate of eradicating HCV exceeds 90%.  The peginterferon-free DAAs carry fewer side effects and can effectively reduce the risks of cirrhosis and liver cancer.

 

Professor Henry L.Y. Chan, Director of the Center for Liver Health at CUHK, remarked, ‘The development of DAAs has opened a new chapter for HCV treatment.  New DAAs does not only cause much fewer side effects, but it also lowers the risk of cirrhosis and liver cancer.  However, the cost of treatment involving DAAs is notably higher and the associated drugs have yet to be registered under the Hospital Authority Drug Formulary, which means they are not readily available to the general public.  Although conventional HCV treatment cannot guarantee eradication of HCV, we still encourage patients to receive treatment to control the disease.’  The Center for Liver Health also calls upon the public to avoid sharing syringes and unprotected sex to prevent contraction of HCV.

 

The Center for Liver Health at CUHK is dedicated to the education and prevention of HCV.In addition to offering screening and related services to patients in need, the Center also organizes health talks to raise awareness among the public and the medical professionals on HCV, its social impacts and treatment methods.  Interested parties are welcome to contact the Center at 3505 1298.

 

Prof. Henry L.Y. CHAN, Director, and Professor Vincent W. S. WONG

Prof. Henry L.Y. CHAN (right), Director, and Professor Vincent W. S. WONG, Deputy Director, Center for Liver Health, CUHK.

More Press Releases

CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

CUHK Develops Lifestyle Modification Program for Fatty Liver Patients 60% Patients Recovered Without Use of Drugs

Health Campaign
CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

CUHK-HCC Score Accurately Predicts Risk of Liver Cancer in Chronic Hepatitis B Patients Receiving Antiviral Therapy

Research
CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

CUHK Estimates One Million Hong Kong People are Suffering from Fatty Liver Disease

Research
CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

CUHK Discovers the Use of Hepatitis B Surface Antigen Level as a New Marker for Disease Control in Chronic Hepatitis B Patients

Research
CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

CUHK Discovers High Prevalence of Colorectal Polyps among Fatty Liver Patients

Research
CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

CUHK Discovers Fatty Liver Causing Severe Liver Fibrosis or Cirrhosis in 1 Out of 5 Diabetic Patients

Research
CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

CUHK Latest Research Reveals over 100,000 New Non-alcoholic Fatty Liver Cases in Hong Kong Annually

Research
CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

CUHK Received Four Ministry of Education Higher Education Outstanding Scientific Research Output Awards The Highest Share among Hong Kong Institutions

Awards and honors
CUHK Pioneers the Use of a New Non-Invasive Imaging Technology to Measure Fatty Liver - a problem affecting 27% of the adult population in HK

CUHK Pioneers the Use of a New Non-Invasive Imaging Technology to Measure Fatty Liver - a problem affecting 27% of the adult population in HK

Research
Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Antiviral Therapy Can Prevent Liver Cancer Recurrence CUHK Represents HK to Draw Up Asian Pacific Treatment Guideline for Chronic Hepatitis B

Research
CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

CUHK and French Researchers Pioneer the Use of Non-Invasive Imaging Technology – New XL Probe to Assess Liver Disease in Obese Patients

Research
CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

CU Medicine Study Shows Liver Injury is Common and Prognostic in COVID-19 Patients

Research
CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

CUHK Study Reveals Patients with Recovery of Hepatitis B Still at Risk of Liver Cancer

Research
CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

CUHK Reveals Non-Alcoholic Fatty Liver Disease Afflicts Even the Non-Obese

Research
Three CUHK Scholars Named Croucher Senior Research Fellow 2011-12

Three CUHK Scholars Named Croucher Senior Research Fellow 2011-12

Awards and honors

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.